Natco Pharma unveils new drug

By Our Corporate Bureau | 26 Jun 2004

Hyderabad:Natco Pharma Ltd has announced the launch of Ganciclovir said to be one of the latest generation drugs used in the treatment and prevention of cytomegalovirus. The drug was launched in 250 mg capsules and 500 ml injection forms.

In a statement the company said cytomegalovirus retinitis is a potential threat in immuno-compromised and AIDS patients, patients undergoing chemotherapy and recipients of organ transplants. In these cases, cytomegalovirus could lead to irreparable blindness, the company said.

According to the company, Ganciclovir, on its intake, converts itself to a triphosphate and effectively inhibits DNA polymerases and consequently its replication. The drug would effectively combat the eyesight threatening infection.

Latest articles

India plans a Rs9,000-crore boost to EV battery production

Skoda-Volkswagen India faces Rs12,000-cr tax evasion charge

India’s wholesale price inflation slows to 1.89% in November

DRDO successfully flight-tests solid fuel ducted ramjet booster missile

Reliance acquires 74% stake in Navi Mumbai IIA for Rs1,628 crore

Hinduja Group to acquire Reliance Capital by end-January

Centre to open 85 new Kendriya Vidyalayas, 28 Navodaya Vidyalayas in 2025-26

RBI keeps repo rate steady, cuts cash reserve ratio to 4%

Defence ministry approves Rs21,772-cr equipment acquisition for armed forces